Wire · regulatory
The FTC's Targeting of Drug-Inflating PBM Practices
◆ Sectors
Healthtech Infrastructure
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 25 August 2026 · Fusion42 review
The U.S. Federal Trade Commission (FTC) is intensifying scrutiny and enforcement against pharmacy benefit managers (PBMs) accused of inflating drug prices. This crackdown aims to enhance transparency and reduce drug costs in the pharmaceutical supply chain.
This Wire brief sits within Fusion42's coverage of Healthtech Infrastructure.
◆ ◆ The Wire takeaway
You will face tighter rules on how drug prices flow through your supply chain. This opens new room to pitch transparency tools and means PBMs can no longer assume unchecked pricing power.
◆ Coverage
1 source · 10 Aug 2026
◆ Related on Wire
◆ Topics
Healthtech Infrastructureftcpharmacy-benefit-managersdrug-pricingregulatory-crackdownpharma-costs